Fumiko Imai's MSc Defence
Date and Time
Location
ANNU 141 and Teams: https://teams.microsoft.com/l/meetup-join/19%3ameeting_NzVmMGU3ZDctMDkyMi00OGY5LThkZjYtMjhmZTYxODEwZGU3%40thread.v2/0?context=%7b%22Tid%22%3a%22be62a12b-2cad-49a1-a5fa-85f4f3156a7d%22%2c%22Oid%22%3a%22efd0fc96-c177-48e3-9e37-73ab2f64dde4%22%7d
Details
Re-evaluating Recommendations for Eicosapentaenoic acid (EPA) and Do-cosahexaenoic acid (DHA) for Adult Dogs: A Dose-Response Study on Lipid In-corporation, Antioxidant Status, Lipid Peroxidation, and Inflammation
Abstract:
The anti-inflammatory benefits of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in dogs are well-established, yet optimal levels remain unclear. This study assessed the effects of EPA+DHA supplementation above NRC safe tolerable level on healthy adult dogs over eight weeks. Dogs received LOW (0.03), MOD (0.45), or HIGH (0.71) g/kg BW0.75 of EPA+DHA. Phospholipid incorporation exhibit-ed distinct patterns across lipid fractions: the MOD dose resulted in greater incorporation in phosphatidylcho-line (PC) and lysophosphatidylcholine (LysoPC), with no further increase observed at the HIGH dose. In contrast, the highest incorporation in sphingomyelin (SM) occurred at the HIGH dose. α-Tocopherol levels were lower in the HIGH group, suggesting increased antioxidant utilization, while malondialdehyde (MDA) remained stable. Cytokines showed no treatment effects, but a time-dependent increase suggested possible seasonal variation. No adverse effects were noted, supporting the safety of higher supplementation and suggesting the need for updated NRC guidelines.